Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SciSparc Ltd. ( (SPRC) ) just unveiled an update.
On March 10, 2026, SciSparc’s subsidiary NeuroThera Labs Inc. agreed to acquire a 54.01% controlling stake in quantum technology firm CliniQuantum Ltd. for 56.6 million NeuroThera shares, valuing the equity portion of the deal at about $9.46 million. The transaction also includes up to $2.5 million in milestone-based earn-out payments over three years, finder’s fees in NeuroThera shares, and is expected to close around March 31, 2026, after which SciSparc’s ownership in NeuroThera would drop from roughly 75% to about 43.86%, signaling a strategic shift that deepens its exposure to quantum-enabled clinical trial technology while diluting its direct control of the CNS-focused subsidiary.
More about SciSparc Ltd.
SciSparc Ltd. is a clinical-stage pharmaceutical company that operates primarily through its majority-owned subsidiary NeuroThera Labs Inc., in which it currently holds about 75%. The group focuses on developing cannabinoid-based therapies, including THC- and CBD-derived candidates for Tourette syndrome, Alzheimer’s-related agitation, autism spectrum disorder and status epilepticus, and also has a hemp seed oil products business on Amazon.
Average Trading Volume: 134,738
Technical Sentiment Signal: Sell
Current Market Cap: $2.18M
Find detailed analytics on SPRC stock on TipRanks’ Stock Analysis page.